GlassScriptPhysician profile
Monica M Deitz
NPI 1356902837
$1,431.84
in general payments reported to CMS, 2019-2025
13 companies · $753 in 2025
The $753 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $63.69 · 2022: $99.05 · 2023: $171 · 2024: $346 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.83 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $255.30 | 2025 | Rezdiffra |
| Astrazeneca Pharmaceuticals LP | $250.91 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Ipsen Biopharmaceuticals, INC | $231.54 | 2025 | Bylvay, Iqirvo |
| Novo Nordisk INC | $189.30 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $132.13 | 2021-2025 | Mounjaro, Zepbound |
| Gilead Sciences, INC. | $121.84 | 2025 | Livdelzi |
| Xeris Pharmaceuticals, INC. | $65.68 | 2022 | |
| Exact Sciences Corporation | $57.43 | 2024 | Cologuard Collection Kit |
| Amgen INC. | $45.21 | 2023-2025 | Repatha, Otezla, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.07 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.05 | 2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $16.94 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.44 | 2024 | Trintellix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Deitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.